Panitumumab in Patients with KRAS Wild-Type Colorectal Cancer after Progression on Cetuximab

PURPOSE: Cetuximab and panitumumab are monoclonal antibodies that target the epidermal growth factor receptor (EGFR) and are approved for the treatment of patients with KRAS wild-type meta-static colorectal cancer. There are no data that describe the activity of panitumumab in patients with progress...

詳細記述

保存先:
書誌詳細
主要な著者: Wadlow, Raymond C., Hezel, Aram F., Abrams, Thomas A., Blaszkowsky, Lawrence S., Fuchs, Charles S., Kulke, Matthew H., Kwak, Eunice L., Meyerhardt, Jeffrey A., Ryan, David P., Szymonifka, Jackie, Wolpin, Brian M., Zhu, Andrew X., Clark, Jeffrey W.
フォーマット: Artigo
言語:Inglês
出版事項: AlphaMed Press 2012
主題:
Clinical Trial Reports
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3267814/
https://ncbi.nlm.nih.gov/pubmed/22210091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2011-0452
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料